Regulus Therapeutics Director Sells $6,600 in Stock (RGLS)
Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc sold 1,000 shares of the stock on the open market in a transaction dated Wednesday, July 30th. The stock was sold at an average price of $6.60, for a total value of $6,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Regulus Therapeutics (NASDAQ:RGLS) traded down 2.97% during mid-day trading on Friday, hitting $6.20. The stock had a trading volume of 64,548 shares. Regulus Therapeutics has a one year low of $5.40 and a one year high of $11.88. The stock’s 50-day moving average is $7.22 and its 200-day moving average is $8.01. The company’s market cap is $268.8 million.
Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, May 8th. The company reported ($0.30) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.14) by $0.16. On average, analysts predict that Regulus Therapeutics will post $-0.84 earnings per share for the current fiscal year.
A number of research firms have recently commented on RGLS. Analysts at Zacks upgraded shares of Regulus Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Tuesday, June 17th. They now have a $7.80 price target on the stock. Finally, analysts at Brinson Patrick initiated coverage on shares of Regulus Therapeutics in a research note on Tuesday, May 13th. They set an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Regulus Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $14.76.
Regulus Therapeutics Inc, is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.